tetano
Editor, Senior Moderator
Anal Chem
. 2024 Mar 13.
doi: 10.1021/acs.analchem.3c05144. Online ahead of print. Overlaid Lateral Flow Immunoassay for the Simultaneous Detection of Two Variant-Specific SARS-CoV-2 Neutralizing Antibodies
Wanwisa Deenin[SUP] 1 2 [/SUP], Nanthika Khongchareonporn[SUP] 2 3 [/SUP], Kiat Ruxrungtham[SUP] 4 5 6 [/SUP], Chutitorn Ketloy[SUP] 4 5 7 [/SUP], Nattiya Hirankarn[SUP] 8 [/SUP], Kittikhun Wangkanont[SUP] 9 10 [/SUP], Sirirat Rengpipat[SUP] 11 [/SUP], Abdulhadee Yakoh[SUP] 2 3 [/SUP], Sudkate Chaiyo[SUP] 2 3 [/SUP]
Affiliations
COVID-19 vaccines have been provided to the general public to build immunity since the 2019 coronavirus pandemic. Once vaccinated, SARS-CoV-2 neutralizing antibodies (NAbs-COVID-19) are needed for excellent protection against COVID-19. However, monitoring NAbs-COVID-19 is complicated and requires hospital visits. Moreover, the resulting NAbs-COVID-19 are effective against different strains of COVID-19 depending on the type of vaccine received. Here, an overlaid lateral flow immunoassay (O-LFIA) was developed for the simultaneous detection of two NAbs-COVID-19 against different virus strains, Delta and Omicron. The O-LFIA was visualized with two T-lines with a single device using competition between the free antigen and the antigen-binding antibody. Angiotensin-converting enzyme 2 (ACE2) immobilized on the T-line binds to the antigen remaining after antibody binding. Under the optimum conditions, the proposed device exhibited 50% inhibition concentrations (IC[SUB]50[/SUB] values) of 45.1 and 53.6 ng/mL for the Delta and Omicron variants, respectively. Additionally, the proposed platform was applied to real-world samples of animal and human serum, and the developed immunoassay provided results that were in good agreement with those obtained with the standard method. In conclusion, this developed O-LFIA can be used as an alternative method to detect NAbs-COVID-19 and can be enabled for future advancements toward commercialization.
. 2024 Mar 13.
doi: 10.1021/acs.analchem.3c05144. Online ahead of print. Overlaid Lateral Flow Immunoassay for the Simultaneous Detection of Two Variant-Specific SARS-CoV-2 Neutralizing Antibodies
Wanwisa Deenin[SUP] 1 2 [/SUP], Nanthika Khongchareonporn[SUP] 2 3 [/SUP], Kiat Ruxrungtham[SUP] 4 5 6 [/SUP], Chutitorn Ketloy[SUP] 4 5 7 [/SUP], Nattiya Hirankarn[SUP] 8 [/SUP], Kittikhun Wangkanont[SUP] 9 10 [/SUP], Sirirat Rengpipat[SUP] 11 [/SUP], Abdulhadee Yakoh[SUP] 2 3 [/SUP], Sudkate Chaiyo[SUP] 2 3 [/SUP]
Affiliations
- PMID: 38478766
- DOI: 10.1021/acs.analchem.3c05144
COVID-19 vaccines have been provided to the general public to build immunity since the 2019 coronavirus pandemic. Once vaccinated, SARS-CoV-2 neutralizing antibodies (NAbs-COVID-19) are needed for excellent protection against COVID-19. However, monitoring NAbs-COVID-19 is complicated and requires hospital visits. Moreover, the resulting NAbs-COVID-19 are effective against different strains of COVID-19 depending on the type of vaccine received. Here, an overlaid lateral flow immunoassay (O-LFIA) was developed for the simultaneous detection of two NAbs-COVID-19 against different virus strains, Delta and Omicron. The O-LFIA was visualized with two T-lines with a single device using competition between the free antigen and the antigen-binding antibody. Angiotensin-converting enzyme 2 (ACE2) immobilized on the T-line binds to the antigen remaining after antibody binding. Under the optimum conditions, the proposed device exhibited 50% inhibition concentrations (IC[SUB]50[/SUB] values) of 45.1 and 53.6 ng/mL for the Delta and Omicron variants, respectively. Additionally, the proposed platform was applied to real-world samples of animal and human serum, and the developed immunoassay provided results that were in good agreement with those obtained with the standard method. In conclusion, this developed O-LFIA can be used as an alternative method to detect NAbs-COVID-19 and can be enabled for future advancements toward commercialization.